These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30253211)

  • 1. Physicochemical and biopharmaceutical characterization of celecoxib nanoparticle: Avoidance of delayed oral absorption caused by impaired gastric motility.
    Yakushiji K; Ogino M; Suzuki H; Seto Y; Sato H; Onoue S
    Int J Pharm; 2018 Dec; 552(1-2):453-459. PubMed ID: 30253211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-Emulsifying Drug Delivery System of Celecoxib for Avoiding Delayed Oral Absorption in Rats with Impaired Gastric Motility.
    Yakushiji K; Sato H; Ogino M; Suzuki H; Seto Y; Onoue S
    AAPS PharmSciTech; 2020 May; 21(5):135. PubMed ID: 32419073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib-Loaded Self-micellizing Solid Dispersion Suppresses Its Delayed Absorption in Rats with Impaired Gastrointestinal Motility.
    Ogino M; Yakushiji K; Suzuki H; Yamauchi Y; Seto Y; Sato H; Onoue S
    Chem Pharm Bull (Tokyo); 2023; 71(10):787-791. PubMed ID: 37779081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amorphous Solid Dispersion of Meloxicam Enhanced Oral Absorption in Rats With Impaired Gastric Motility.
    Suzuki H; Yakushiji K; Matsunaga S; Yamauchi Y; Seto Y; Sato H; Onoue S
    J Pharm Sci; 2018 Jan; 107(1):446-452. PubMed ID: 28551427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of celecoxib poly(lactic-co-glycolic) acid nanoformulation on drug pharmacodynamics and pharmacokinetics in rats.
    Harirforoosh S; West KO; Murrell DE; Denham JW; Panus PC; Hanley GA
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4818-4829. PubMed ID: 27906418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
    Ochi M; Inoue R; Yamauchi Y; Yamada S; Onoue S
    Pharm Res; 2013 Feb; 30(2):377-86. PubMed ID: 22983645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats.
    Choi JS; Ahn JB; Park JS
    Int J Pharm; 2019 Jan; 555():135-145. PubMed ID: 30458259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and biopharmaceutical characterization of amorphous solid dispersion of nobiletin, a citrus polymethoxylated flavone, with improved hepatoprotective effects.
    Onoue S; Nakamura T; Uchida A; Ogawa K; Yuminoki K; Hashimoto N; Hiza A; Tsukaguchi Y; Asakawa T; Kan T; Yamada S
    Eur J Pharm Sci; 2013 Jul; 49(4):453-60. PubMed ID: 23707470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous carbon with spherical pores as a carrier for celecoxib with needle-like crystallinity: improve dissolution rate and bioavailability.
    Zhu W; Zhao Q; Sun C; Zhang Z; Jiang T; Sun J; Li Y; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():13-20. PubMed ID: 24863191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization.
    Suzuki H; Moritani T; Morinaga T; Seto Y; Sato H; Onoue S
    Int J Pharm; 2017 Mar; 519(1-2):213-219. PubMed ID: 28093327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of microenvironmental pH of nanoparticles for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib.
    Ran Woo M; Bak YW; Cheon S; Suk Kim J; Hun Ji S; Park S; Woo S; Oh Kim J; Giu Jin S; Choi HG
    Int J Pharm; 2024 Jun; 659():124179. PubMed ID: 38692498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
    Hyun SM; Lee BJ; Abuzar SM; Lee S; Joo Y; Hong SH; Kang H; Kwon KA; Velaga S; Hwang SJ
    Int J Pharm; 2019 Jan; 554():61-71. PubMed ID: 30347274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel nanoparticle formulation of thymoquinone with a cold wet-milling system and its pharmacokinetic analysis.
    Nihei T; Suzuki H; Aoki A; Yuminoki K; Hashimoto N; Sato H; Seto Y; Onoue S
    Int J Pharm; 2016 Sep; 511(1):455-461. PubMed ID: 27451272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.
    Zhao P; Jiang H; Jiang T; Zhi Z; Wu C; Sun C; Zhang J; Wang S
    Eur J Pharm Sci; 2012 Apr; 45(5):639-47. PubMed ID: 22251657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations.
    Ibrahim MM; Abd-Elgawad AH; Soliman OA; Jablonski MM
    J Pharm Sci; 2016 Dec; 105(12):3691-3701. PubMed ID: 27789031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
    Ha ES; Choo GH; Baek IH; Kim MS
    Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical Study on Nobiletin-Loaded Amorphous Solid Dispersion with Improved Hypouricemic Effect.
    Nihei T; Ushiro E; Sato H; Onoue S
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism for increasing the oral bioavailability of poorly water-soluble drugs using uniform mesoporous carbon spheres as a carrier.
    Wang T; Zhao P; Zhao Q; Wang B; Wang S
    Drug Deliv; 2016; 23(2):420-8. PubMed ID: 24870199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
    Ghanavati R; Taheri A; Homayouni A
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
    Onoue S; Sato H; Ogawa K; Kawabata Y; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
    Int J Pharm; 2010 Oct; 399(1-2):94-101. PubMed ID: 20705124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.